JP2017523984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523984A5 JP2017523984A5 JP2017506286A JP2017506286A JP2017523984A5 JP 2017523984 A5 JP2017523984 A5 JP 2017523984A5 JP 2017506286 A JP2017506286 A JP 2017506286A JP 2017506286 A JP2017506286 A JP 2017506286A JP 2017523984 A5 JP2017523984 A5 JP 2017523984A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- pharmaceutical composition
- ox40l
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032959P | 2014-08-04 | 2014-08-04 | |
| US62/032,959 | 2014-08-04 | ||
| PCT/US2015/043408 WO2016022468A1 (en) | 2014-08-04 | 2015-08-03 | Antagonistic anti-ox40l antibodies and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523984A JP2017523984A (ja) | 2017-08-24 |
| JP2017523984A5 true JP2017523984A5 (enExample) | 2018-08-30 |
| JP6628787B2 JP6628787B2 (ja) | 2020-01-15 |
Family
ID=55264394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506286A Active JP6628787B2 (ja) | 2014-08-04 | 2015-08-03 | 拮抗性抗ｏｘ４０ｌ抗体およびそれらの使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10167339B2 (enExample) |
| EP (1) | EP3194445A4 (enExample) |
| JP (1) | JP6628787B2 (enExample) |
| CN (1) | CN107074951B (enExample) |
| AU (1) | AU2015301338C1 (enExample) |
| IL (1) | IL250428B (enExample) |
| WO (1) | WO2016022468A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US20220372153A1 (en) * | 2015-03-03 | 2022-11-24 | Kymab Limited | Synergistic combinations of ox40l antibodies for the treatment of gvhd |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| US9434785B1 (en) | 2015-04-30 | 2016-09-06 | Kymab Limited | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| WO2018170764A1 (zh) * | 2017-03-22 | 2018-09-27 | 深圳市博奥康生物科技有限公司 | 一种用于 RNAi 的载体及其应用 |
| JP7282760B2 (ja) * | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| CN108458964A (zh) * | 2017-10-31 | 2018-08-28 | 天津协和华美医学诊断技术有限公司 | 一种抗体组合物及其在淋巴浆细胞性淋巴瘤微小残留检测中的应用 |
| EA202192488A1 (ru) * | 2019-03-12 | 2022-02-08 | Юниверсити Хелт Нетворк | Антитела против tsg-6 и их применения |
| MX2022006881A (es) * | 2019-12-06 | 2022-07-11 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l. |
| BR112022021450A2 (pt) * | 2020-04-24 | 2022-12-27 | Millennium Pharm Inc | O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada |
| CN117440967A (zh) * | 2020-12-09 | 2024-01-23 | 怡诺安有限公司 | 抗OX40L抗体、抗OX40L/抗TNFα双特异性抗体及其用途 |
| KR102705172B1 (ko) * | 2020-12-09 | 2024-09-11 | 에이치케이이노엔 주식회사 | 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도 |
| US20230235069A1 (en) * | 2021-08-10 | 2023-07-27 | Kymab Limited | Treatment of atopic dermatitis |
| KR20260047587A (ko) * | 2023-08-04 | 2026-04-08 | 포르비타 바이오로직스 인코포레이티드 | 항-ox40l 항체 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3914342B2 (ja) * | 1997-09-25 | 2007-05-16 | 武田薬品工業株式会社 | ｇｐ３４結合阻害物を有効成分として含有する医薬組成物 |
| US7291331B1 (en) * | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| TWI309240B (en) * | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| US7812133B2 (en) * | 2005-12-16 | 2010-10-12 | Genentech, Inc | Anti-OX40L antibodies and methods using same |
| HRP20251657T1 (hr) * | 2009-12-14 | 2026-02-13 | Ablynx N.V. | Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba |
| WO2012015696A1 (en) | 2010-07-26 | 2012-02-02 | Baylor Research Institute | Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer |
-
2015
- 2015-08-03 CN CN201580052180.0A patent/CN107074951B/zh active Active
- 2015-08-03 EP EP15829426.4A patent/EP3194445A4/en active Pending
- 2015-08-03 WO PCT/US2015/043408 patent/WO2016022468A1/en not_active Ceased
- 2015-08-03 AU AU2015301338A patent/AU2015301338C1/en active Active
- 2015-08-03 US US15/501,526 patent/US10167339B2/en active Active
- 2015-08-03 JP JP2017506286A patent/JP6628787B2/ja active Active
-
2017
- 2017-02-02 IL IL250428A patent/IL250428B/en active IP Right Grant
-
2018
- 2018-12-05 US US16/210,188 patent/US10570208B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501669A5 (enExample) | ||
| CA3036912C (en) | Antibody specifically binding to pd-1 and functional fragment thereof | |
| JP2012501670A5 (enExample) | ||
| JP2019527553A5 (enExample) | ||
| JP2017531427A5 (enExample) | ||
| JP2019535670A5 (enExample) | ||
| JP2023551027A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| TW201833141A (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| IL261666B1 (en) | Binding proteins and methods of use thereof | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| JP2018516853A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| JP2021530244A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2011207882A5 (enExample) | ||
| JP2014529590A5 (enExample) | ||
| JP2011527899A5 (enExample) | ||
| JP2024029261A5 (enExample) | ||
| JP2021502984A5 (enExample) | ||
| JP2023540526A5 (enExample) | ||
| AU2018263196A1 (en) | Anti-interferon gamma antibodies and uses thereof | |
| US12037390B2 (en) | Leptin antibodies and method of reducing leptin | |
| JP2016523235A5 (enExample) | ||
| CN104955846B (zh) | 人源化抗hmgb1抗体或其抗原结合性片段 |